Grifols Therapeutics LLC

Nasdaq GRFS · New York, NY

Works in Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Neurology · Oncology · Respiratory

Grifols Therapeutics LLC is a clinical trial sponsor based in New York, NY, listed as Nasdaq GRFS. It has 4 active clinical trials with 756 planned participants, across 9 therapeutic areas. Since 2021 it has completed 10 trials and stopped 4 early.

Trial track record · since 2021

4Active trials756 planned participants
10Completed12 with results posted
4Stopped early29% of finished trials

Financials · Nasdaq GRFS

Cash and equivalents
R&D expense
Net income (loss)
Cash runway

Pipeline · 4 active trials

StageTrialStatus

Questions about Grifols Therapeutics LLC

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-26.

Approve Suite is not affiliated with Grifols Therapeutics LLC.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.